Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised Dutch PEERS (TWENTE II) trial

Liefke C. van der Heijden, Marlies M. Kok, Marije M. Löwik, Peter W. Danse, Gillian A.J. Jessurun, Raymond W.M. Hautvast, Gert K. van Houwelingen, Martin G. Stoel, Marc Hartmann, Gerard C.M. Linssen, Carine J.M. Doggen, Clemens Von Birgelen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

12 Citations (Scopus)
63 Downloads (Pure)


Aims: The aim of this report was to assess the three-year safety and efficacy of implanting newer-generation Resolute Integrity zotarolimus-eluting stents (ZES) versus PROMUS Element everolimus-eluting stents (EES) in all-comers.

Methods and results: In the randomised, multicentre, investigator-initiated Dutch PEERS trial, a total of 1,811 all-comers were 1:1 randomly assigned to treatment with ZES versus EES. A total of 1,293 patients (72%) were treated for complex lesions and 455 patients (25%) were treated for multiple lesions. The primary endpoint target vessel failure (TVF) is a composite of cardiac death, target vessel-related myocardial infarction or target vessel revascularisation. Adverse clinical events were independently adjudicated. Three-year follow-up data were obtained in 1,807 patients (99.8%, four withdrawals). Both the ZES and EES groups showed favourable outcomes with a similar incidence of TVF (10.7% vs. 10.3%; pLog-rank =0.77) and the individual components thereof: cardiac death (3.2% vs. 3.1%; pLog-rank=0.87), target vessel-related myocardial infarction (2.8% vs. 2.2%; pLog-rank =0.44) and target vessel revascularisation (6.0% vs. 6.2%; pLog-rank =0.87). In addition, the incidence of definite or probable stent thrombosis was similar for patients treated with ZES versus EES (1.4% vs. 1.1%; pLog-rank =0.66).

Conclusions: The safety and efficacy of treating all-comers with newer-generation Resolute Integrity and PROMUS Element stents was found to be extended up to three years.

Original languageEnglish
Pages (from-to)2128-2131
Number of pages4
Issue number17
Publication statusPublished - 1 Apr 2017



  • Newer-generation drug-eluting stent
  • Percutaneous coronary intervention
  • PROMUS Element everolimus-eluting stent
  • Resolute integrity zotarolimus-eluting stent

Cite this